Trodelvy (Sacituzumab govitecan-hziy)

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used to treat adult patients with:

• metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
• locally advanced/metastatic urothelial cancer (mUC) who have previously treated with a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. 

The recommended dose is 10 mg/kg weekly on Days 1 and 8 of each 21-day cycle, or until disease progression or unacceptable toxicity occurs. One should avoid substituting or combining Trodelvy with other irinotecan-containing medications. Administer only as an intravenous infusion, not as a bolus. Pre-infusion medicine and close monitoring are recommended, as well as necessary treatment changes to manage side effects.

• Sacituzumab Govitecan-hziy can cause severe or life-threatening neutropenia. Withhold it for absolute neutrophil count below 1500/mm3 on Day 1’st of any cycle or neutrophil count below 1000/mm3 on Day 8’th of any cycle. Withhold it for neutropenic fever. 
• Trodelvy breast cancer drug can cause severe diarrhea. Withhold it for Grade 3-4 diarrhea at the juncture of scheduled treatment administration and resume when resolved to ≤ Grade 1.
• Sacituzumab Govitecan-hziy can cause severe and life-threatening hypersensitivity. Pre-infusion drug for patients receiving sacituzumab govitecan hziy is recommended. Observe patients precisely for infusion-related reactions during each infusion and for at least 30 minutes following completion of each infusion. 
• Patients who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at greater risk for neutropenia and may be at greater risk for other adverse reactions following starting of trodelvy 180 mg treatment.
• Precisely assess patients with reduced UGT1A1 activity for the severe neutropenia. The apt dose for patients who are homozygous for UGT1A1*28 is not specified and should be considered based on the tolerance to treatment. 
• Mechanism of action suggest that the trodelvy therapy can be responsible for causing teratogenicity and/or embryo-fetal lethality in case administered to a pregnant woman.

What documents are required to import Trodelvy?

Trodelvy (Sacituzumab govitecan-hziy) injection can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the Government of the respective country).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor.
• Import permit if applicable.

Is Trodelvy available worldwide?

Trodelvy (Sacituzumab govitecan-hziy) injection is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.

Urgent Meds facilitates the import of critical medications like Trodelvy globally, ensuring the named patient supply (NPS). Urgent Meds is the facilitator that provides essential support for:

• Availability of Trodelvy: Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
• Trodelvy available in India: Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Bangalore, Pune, etc.
• Determining Medicine Price.
• Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

Trodelvy can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of Trodelvy (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).

We assure quality and worldwide delivery as per the buyer’s specifications.

Urgent Meds is able to source Trodelvy from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Trodelvy®?

Sacituzumab Govitecan-hziy is the Generic Name for the trade name drug Trodelvy®.

Is Trodelvy® approved by the FDA?

Yes, Trodelvy® is approved by the FDA. Date of approval: April 22, 2020.

What is Trodelvy®?

Trodelvy is a kind of medicine named an antibody-drug conjugate (ADC). Unlike other existing traditional chemotherapy, an antibody-drug conjugate contains three parts: an antibody, an anti-cancer medicine, and a linker.

What is the dosage and form of Trodelvy® supplied?

Trodelvy® is supplied for injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial.

What are the most common side effects due to Trodelvy®?

The most common side effects due to Trodelvy® include: nausea, diarrhea, fatigue, neutropenia, anemia, vomiting, alopecia, decreased appetite, constipation, rash, and abdominal pain.

How much does Trodelvy® cost in India?

The Trodelvy cost in India is reasonably economical. To procure this mTNBC medicine authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Trodelvy®?

Store vials of Trodelvy in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of reconstitution. Do not freeze.

How long is treatment with Trodelvy?

Trodelvy is a type of treatment called an antibody-drug conjugate (ADC) that is designed to work differently than traditional chemotherapy.

Is Trodelvy a chemo?

Trodelvy is a type of treatment called an antibody-drug conjugate (ADC) that is designed to work differently than traditional chemotherapy.

How many cycles of Trodelvy?

The recommended dosage of Trodelvy is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity.

Who is eligible for Trodelvy?

Trodelvy is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment.

What is the success rate of Sacituzumab?

In clinical trials, sacituzumab govitecan has demonstrated high efficacy. In the IMMU-132 trial, the ORR was found to be 33.3%, including a complete response in three patients. The clinical benefit rate, including stable disease for more than six months, was 45.4%.

Is Trodelvy available in Asia?

Trodelvy injection is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.

How can I get Trodelvy injection?

Urgent Meds can facilitate the supply of Trodelvy (prescription medicine) to locations worldwide while adhering to legal requirements.

Will I lose my hair on Trodelvy?

Sacituzumab govitecan may cause hair loss. Any hair loss caused should be temporary, and in most cases, your hair will begin to grow back once your treatment has ended.

Where is Trodelvy available in India?

Trodelvy is available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune, etc.).